Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, 510060, China; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, 510060, China.
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, 510060, China.
Cancer Lett. 2024 Aug 28;598:217113. doi: 10.1016/j.canlet.2024.217113. Epub 2024 Jul 14.
Colorectal cancer (CRC) ranks as the third most common cancer and the second leading cause of cancer-related deaths. According to clinical diagnosis and treatment, liver metastasis occurs in approximately 50 % of CRC patients, indicating a poor prognosis. The unique immune tolerance of the liver fosters an immunosuppressive tumor microenvironment (TME). In the context of tumors, numerous membrane and secreted proteins have been linked to tumor immune evasion as immunomodulatory molecules, but much remains unknown about how these proteins contribute to immune evasion in colorectal cancer liver metastasis (CRLM). This article reviews recently discovered membrane and secreted proteins with roles as both immunostimulatory and immunosuppressive molecules within the TME that influence immune evasion in CRC primary and metastatic lesions, particularly their mechanisms in promoting CRLM. This article also addresses screening strategies for identifying proteins involved in immune evasion in CRLM and provides insights into potential protein targets for treating CRLM.
结直肠癌(CRC)位居第三大常见癌症之列,也是癌症相关死亡的第二大主要原因。根据临床诊断和治疗,约 50%的 CRC 患者发生肝转移,预示着预后不良。肝脏独特的免疫耐受促进了免疫抑制性肿瘤微环境(TME)。在肿瘤中,许多膜和分泌蛋白已被确定为具有免疫调节功能的分子,可逃避肿瘤免疫,但这些蛋白如何促进结直肠癌肝转移(CRLM)中的免疫逃避仍知之甚少。本文综述了最近发现的具有免疫刺激和免疫抑制分子作用的膜和分泌蛋白,这些蛋白在 TME 中影响 CRC 原发和转移病变中的免疫逃避,特别是它们在促进 CRLM 中的机制。本文还讨论了用于鉴定 CRLM 中免疫逃避相关蛋白的筛选策略,并为治疗 CRLM 提供了潜在的蛋白靶点。